The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
 
Fortunato Ciardiello
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; BeiGene; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Jacobio (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); TRACON Pharma (Inst); Tyrogenex (Inst)
 
Andres Cervantes
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Novartis; Roche/Genentech; SERVIER; Takeda
Speakers' Bureau - Merck Serono; Roche; SERVIER
Research Funding - Johnson & Johnson (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst); Theradex (Inst)
Travel, Accommodations, Expenses - Roche
 
Rainer Karl Brachmann
Employment - Gilead Sciences (I); OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - Gilead Sciences (I); OncoMed
 
Yuting Zhang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Mitch Raponi
Employment - BeiGene; Clovis Oncology
Stock and Other Ownership Interests - BeiGene; Clovis Oncology
 
Heinrich Farin
Employment - BeiGene
Stock and Other Ownership Interests - ARIAD; BeiGene
 
Shen Lin
No Relationships to Disclose